Outlook Therapeutics (OTLK) Payables (2015 - 2026)

Outlook Therapeutics (OTLK) has 12 years of Payables data on file, last reported at $23.5 million in Q1 2026.

• Payables for Q1 2026 came in at $23.5 million, up 18.79% year-over-year; the trailing twelve-month figure through Mar 2026 was $23.5 million (up 18.79% YoY), and the FY2025 annual result was $40.1 million, up 7.3% from the prior year.
• Payables fell to $23.5 million in Q1 2026 per OTLK's latest filing, from $44.0 million in the prior quarter.
• Over five years, Payables peaked at $49.1 million in Q1 2024 and troughed at $4.2 million in Q4 2022.
• A 5-year average of $31.5 million and a median of $37.4 million in 2024 frame the typical range for Payables.
• The sharpest annual moves came in 2022 and 2023: Payables plunged 72.68% in 2022, then soared 859.84% in 2023.
• A 5-year view of Payables shows it stood at $4.2 million in 2022, then soared by 859.84% to $40.0 million in 2023, then rose by 7.28% to $42.9 million in 2024, then gained by 2.43% to $44.0 million in 2025, then plunged by 46.61% to $23.5 million in 2026.
• Business Quant data shows OTLK's Payables at $23.5 million in Q1 2026, $44.0 million in Q4 2025, and $40.1 million in Q3 2025.